# Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection

> **NCT05229991** · PHASE3 · COMPLETED · sponsor: **Soroka University Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Hepatitis D, Chronic

## Interventions

- **DRUG:** Lonafarnib
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT05229991
- **Lead sponsor:** Soroka University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-15
- **Primary completion:** 2025-02-05
- **Final completion:** 2025-02-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05229991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05229991, "Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05229991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*